Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

SOPHIA ANTIPOLIS, France, Nov. 12 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that results from the first pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 301 study) were presented on November 10, 2007 at the 71st annual meeting of the American College of Rheumatology (ACR), in Boston, Massachusetts (see NOTE). Naproxcinod is NicOx' lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide Donator (CINOD) class. The presentation contained additional efficacy data to the top-line results announced in 2006 (see press release of October 27, 2006) which showed that naproxcinod met all three co-primary endpoints of the trial. The data showed that both doses of naproxcinod (750 mg and 375 mg bid) had superior efficacy to placebo at all time points (2, 6 and 13 weeks). This presentation also contained additional safety and tolerability information, including the gastro-intestinal adverse event rates and blood pressure measurements reported for each of the treatment groups.

Detailed clinical data from the 301 study were presented, including data for each of the three co-primary efficacy endpoints: WOMAC(TM) pain subscale, WOMAC(TM) function subscale and patients' overall rating of disease status. Each of the active treatments (naproxcinod 750 mg, naproxcinod 375 mg and naproxen 500 mg bid) were statistically significantly superior to placebo (p<=0.0002) at 2, 6 and 13 weeks. In addition, standard quality of life scores showed a functional improvement for both naproxcinod doses, as well as for the naproxen group.

At week 13, both doses of naproxcinod (750 mg and 375 mg bid) showed a slight decrease in systolic blood pressure in terms of the mean change from baseline compared to placebo (0.8 and 0.2 mmHg, respectively), while a 2 mmHg increase was observed for naproxen compared to placebo. Patients' blood pressure was measured by a health care professional using
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Redwood Pharma AB has entered into a ... both the US and China , ... hydrogel technology in its lead chronic Dry Eye therapeutic ... technology offers many unique competitive benefits. At lower temperatures, ... low concentrations of polymer the system can be transitioned ...
(Date:7/2/2015)... BGI a annoncé aujourd,hui que son ... situé à Hong Kong ... Pathologists  (Collège des pathologistes américains, ou CAP). Les ... constituent le premier laboratoire clinique de ... du CAP en Chine, car il satisfait les ...
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 ... EPI) announced today that its common shares have been approved ... under the symbol "EPIX". ESSA will begin trading ... its listing on the TSX Venture Exchange under the symbol ... the common shares on the NASDAQ, each of the Company,s ...
Breaking Medicine Technology:Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer ... cancer patients, caregivers and medical professionals to chat with the CHN patient services ... , “Receiving a cancer diagnosis is often the most traumatic experience of a ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a new community ... teamed up with Family Emergency Shelter Coalition (FESCO) and announced a new charity ... created especially to provide emergency services and support for homeless families, all the ...
(Date:7/6/2015)... ... , ... With a new community program in the Livonia, Canton and Plymouth ... a new charity campaign to raise funds in support of the health and safety ... Our Youth is a coalition created especially to educate and empower teens, bringing awareness ...
(Date:7/6/2015)... Rockville, MD (PRWEB) , ... July 06, 2015 , ... ... MD, and Washington, DC, area patients. Kybella is a non-surgical method to ... the use of reducing moderate to severe fat deposits under the chin, commonly known ...
(Date:7/6/2015)... ... July 06, 2015 , ... Diabetes affects many of us and the ... Americans have diabetes, the majority of which are Type 2. However, eight million do ... one in three, have prediabetes (abnormally high blood sugar levels). Without reductions in blood ...
Breaking Medicine News(10 mins):Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2
... following release was issued today by the National Autism ... against three families claiming vaccines caused autism in their ... JR and David Kirby reported Tuesday on the story ... following the MMR vaccine. Last week, Banks, parents were ...
... Objectives, Not Undermine ThemJOPLIN, Mo., Feb. 26 ... U.S. House lawmakers to President Barack Obama urging him ... Senior Care (CPSC) said that while the recently passed ... the nation,s long term care workforce, the White House ...
... to save cancer patients, lives can also destroy their ... oncofertility has advanced the ability of doctors to preserve ... are diagnosed with cancer. Yet, many oncologists aren,t familiar ... A leading oncofertility researcher and a breast surgical oncologist ...
... Calif., Feb. 26 Heart disease, stroke, cancer, ... death in America. These conditions cause extreme ... on patients and their families as well as ... Adverse Childhood Experiences (ACE) Study, an ongoing collaboration ...
... Component to Releasing Addictions Program Now AvailableLOS ANGELES, Feb. ... and optimal performance center, announced today the launch of ... - a customized continuing care program providing sober and ... and a new group component to its Releasing ...
... Feb. 26 On Monday, March 2, the ... to become "The Healthiest Company in Green Bay." The firm ... them at that goal.The 30-person agency is collaborating with Health ... ( www.hatwork.com ). The title of "Healthiest Company in Green ...
Cached Medicine News:Health News:On the Heels of Court Ruling Denying Autism-Vaccine Link, U.S. Federal Court Declares MMR Vaccine Caused Autism in a Young Boy 2Health News:Coalition to Protect Senior Care Praises Bipartisan House Effort to Protect Seniors' Nursing Home Care, LTC Workforce 2Health News:New tool guides doctors to save cancer patients' fertility 2Health News:New tool guides doctors to save cancer patients' fertility 3Health News:The Catalyst Foundation's Groundbreaking ACE Study-Based Services Bring Transformational Change to Healthcare 2Health News:Moonview Sanctuary Announces Two New Offerings for Existing and Potential Clients 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 3
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
Medicine Products: